BioNexus Gene Lab (BGLC) Shares Outstanding (2018 - 2026)

BioNexus Gene Lab's Shares Outstanding history runs 9 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Shares Outstanding rose 34.54% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (up 34.54% YoY), while the FY2025 annual figure was $2.4 million, up 34.54% from the prior year.
• Shares Outstanding came in at $2.4 million for Q1 2026 at BioNexus Gene Lab, roughly flat from $2.4 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $173.7 million in Q2 2023 to a low of $1.8 million in Q4 2023.
• A 5-year average of $28.7 million and a median of $14.5 million in 2022 frame the typical range for Shares Outstanding.
• Across the five-year window, Shares Outstanding slumped 91.67% in 2022 and surged 34.54% in 2025, its largest moves.
• BioNexus Gene Lab's Shares Outstanding stood at $14.5 million in 2022, then plunged by 87.8% to $1.8 million in 2023, then increased by 1.7% to $1.8 million in 2024, then soared by 34.54% to $2.4 million in 2025, then changed by 0.0% to $2.4 million in 2026.
• According to Business Quant data, Shares Outstanding over the past three periods registered $2.4 million, $2.4 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison